Search results
ZYMUTEST Protein S Total
Diagnosis of protein S deficiencies (congenital, acquired or transitory) • Type I deficiency: Partial deficiency of total and free protein S antigen • Type II deficiency: Normal total and free protein S antigen, reduced activity • Type III deficiency: Normal total antigen, decreased activity and free antigen, assay of protein S in clinical studies.
Protein Z, Human
ZYMUTEST HIA, IgGAM Screening
Assessment of the risk to develop HIT/HITT, in patients treated with heparins (unfractionated or LMWH): presence of antibodies is a risk indicator for development of HIT/HITT. Clinical suspicion of HIT during heparin therapy.
ZYMUTEST vWF:CBA (Collagen Binding Assay)
Diagnosis of von Willebrand disease (vWD). Assay of vWF:CBA in clinical samples, as a disease marker or as an indicator for cardiovascular diseases.
BIOPHEN Factor IX (6)
Assay proposed for the measurement of factor IX activity in research applications.
Anti-mouse, goat, IgG, affinity purified, Peroxidase conjugated
TAFI, anti-human, sheep, IgG, Peroxidase conjugated
Epinephrine
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
Collagen
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome, storage pool disease) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.
Arachidonic Acid
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.